Capital International Sarl Buys 60,648 Shares of Abbott Laboratories $ABT

Capital International Sarl increased its stake in shares of Abbott Laboratories (NYSE:ABT) by 19.7% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 368,795 shares of the healthcare product maker’s stock after buying an additional 60,648 shares during the period. Capital International Sarl’s holdings in Abbott Laboratories were worth $46,206,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. Vanguard Group Inc. boosted its holdings in shares of Abbott Laboratories by 1.4% during the 4th quarter. Vanguard Group Inc. now owns 175,556,716 shares of the healthcare product maker’s stock worth $21,995,501,000 after buying an additional 2,402,408 shares during the period. Capital International Investors boosted its holdings in shares of Abbott Laboratories by 2.6% during the 4th quarter. Capital International Investors now owns 63,229,445 shares of the healthcare product maker’s stock worth $7,922,519,000 after buying an additional 1,614,706 shares during the period. Norges Bank bought a new stake in shares of Abbott Laboratories during the 4th quarter worth about $2,938,892,000. Invesco Ltd. boosted its holdings in shares of Abbott Laboratories by 51.0% during the 3rd quarter. Invesco Ltd. now owns 13,951,907 shares of the healthcare product maker’s stock worth $1,868,718,000 after buying an additional 4,713,135 shares during the period. Finally, Ameriprise Financial Inc. boosted its holdings in Abbott Laboratories by 3.8% in the 3rd quarter. Ameriprise Financial Inc. now owns 13,500,829 shares of the healthcare product maker’s stock valued at $1,804,050,000 after purchasing an additional 499,351 shares during the period. Institutional investors own 75.18% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have issued reports on ABT. Sanford C. Bernstein cut their price objective on shares of Abbott Laboratories from $125.00 to $110.00 and set an “outperform” rating for the company in a report on Friday, April 17th. Piper Sandler cut their price objective on shares of Abbott Laboratories from $135.00 to $115.00 and set an “overweight” rating for the company in a report on Friday, April 17th. Benchmark cut their price objective on shares of Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating for the company in a report on Friday, April 17th. TD Cowen cut their price objective on shares of Abbott Laboratories from $137.00 to $115.00 and set a “buy” rating for the company in a report on Friday, April 17th. Finally, Leerink Partners cut their price objective on shares of Abbott Laboratories from $119.00 to $106.00 and set a “market perform” rating for the company in a report on Tuesday, April 21st. Two research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have assigned a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $119.09.

Insider Buying and Selling

In other news, CFO Philip P. Boudreau purchased 2,200 shares of the business’s stock in a transaction dated Thursday, April 23rd. The stock was bought at an average price of $91.50 per share, with a total value of $201,300.00. Following the acquisition, the chief financial officer owned 2,200 shares in the company, valued at approximately $201,300. The trade was a ? increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Daniel J. Starks acquired 10,000 shares of the stock in a transaction that occurred on Monday, April 27th. The shares were bought at an average price of $92.65 per share, with a total value of $926,500.00. Following the completion of the transaction, the director owned 6,751,103 shares in the company, valued at $625,489,692.95. This represents a 0.15% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Corporate insiders own 0.46% of the company’s stock.

Abbott Laboratories Stock Performance

Shares of Abbott Laboratories stock opened at $91.20 on Friday. The company has a 50 day moving average of $92.80 and a 200-day moving average of $109.31. Abbott Laboratories has a 1-year low of $81.97 and a 1-year high of $139.06. The company has a current ratio of 1.39, a quick ratio of 1.01 and a debt-to-equity ratio of 0.56. The company has a market cap of $158.85 billion, a PE ratio of 25.55, a price-to-earnings-growth ratio of 1.52 and a beta of 0.63.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share for the quarter, topping analysts’ consensus estimates of $1.14 by $0.01. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.62%. The company had revenue of $11.16 billion during the quarter, compared to the consensus estimate of $10.99 billion. During the same quarter in the prior year, the firm posted $1.09 EPS. The firm’s quarterly revenue was up 7.8% on a year-over-year basis. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. As a group, equities research analysts forecast that Abbott Laboratories will post 5.48 earnings per share for the current fiscal year.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.